Bulk Pharmaceutical API Sources for BACTROBAN

Bulk Pharmaceutical API Sources for BACTROBAN

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		M7694_SIGMA
Molport		MolPort-003-666-882
Amadis Chemical		A805560
AKos Consulting & Solutions		AKOS015994756
Finetech Industry Limited		FT-0630394

Bulk Active Pharmaceutical Ingredient (API) Sources for BACTROBAN

Last updated: February 19, 2026

This report identifies and analyzes key bulk active pharmaceutical ingredient (API) suppliers for BACTROBAN (mupirocin), a topical antibiotic. The analysis focuses on global manufacturers with established regulatory filings and production capabilities.

What is BACTROBAN and its API?

BACTROBAN is a brand name for the topical antibiotic mupirocin. Mupirocin is an oxazolidinone antibiotic that inhibits bacterial protein synthesis by reversibly binding to and inactivating bacterial isoleucyl-tRNA synthetase. This mechanism of action is distinct from other antibiotic classes, leading to a low incidence of cross-resistance [1].

Mupirocin is primarily used for the treatment of superficial skin infections, including impetigo, folliculitis, and ecthyma, caused by susceptible strains of Staphylococcus aureus (including methicillin-resistant Staphylococcus aureus, MRSA) and Streptococcus pyogenes. It is available in both ointment and cream formulations.

The bulk API is mupirocin calcium, the calcium salt of mupirocin. The chemical name for mupirocin is (2E)-2-methyl-3-[4-(2S,3R,4R,5R)-3,4,5-trihydroxyoxan-2-yl]-1-oxoundec-2-enyl]isonicotinic acid. The molecular formula for mupirocin calcium is C26H44NO9·Ca·H2O, with a molecular weight of 588.76 g/mol.

Who are the Key Bulk Mupirocin API Manufacturers?

The global market for mupirocin API is characterized by a limited number of manufacturers, primarily located in Asia, with significant production capacity and regulatory approvals. These suppliers cater to both generic pharmaceutical companies and branded drug manufacturers.

Key manufacturers include:

• Fuji Fine chemicals Co., Ltd.

  • Location: Japan.
  • Regulatory Status: Holds Drug Master Files (DMFs) with regulatory agencies, including the U.S. Food and Drug Administration (FDA).
  • Production Capacity: Operates manufacturing facilities with a history of producing pharmaceutical-grade mupirocin calcium.
  • Market Presence: Supplies API to global markets for both branded and generic mupirocin formulations.

• Lupin Limited

  • Location: India.
  • Regulatory Status: Registered and approved API manufacturer with multiple international regulatory bodies. Has filed DMFs for mupirocin calcium.
  • Production Capacity: Possesses large-scale API manufacturing capabilities and a broad portfolio of antibiotic APIs.
  • Market Presence: A significant supplier of APIs to regulated markets, including the United States and Europe.

• Divi’s Laboratories Limited

  • Location: India.
  • Regulatory Status: Is a well-established API manufacturer with multiple US FDA and European Directorate for the Quality of Medicines & HealthCare (EDQM) approved facilities. Holds relevant DMFs for mupirocin calcium.
  • Production Capacity: Operates multiple state-of-the-art manufacturing sites with significant output for various APIs.
  • Market Presence: Supplies API to a wide range of pharmaceutical companies globally, including those producing mupirocin-containing products.

• Granules India Limited

  • Location: India.
  • Regulatory Status: Holds DMFs for mupirocin calcium and operates manufacturing sites compliant with international GMP standards.
  • Production Capacity: Has demonstrated capacity for producing high-quality APIs for global pharmaceutical markets.
  • Market Presence: A known supplier of APIs for antibacterial formulations.

What are the Regulatory Requirements for Mupirocin API?

Manufacturing and supplying bulk mupirocin API requires adherence to stringent regulatory standards to ensure product quality, safety, and efficacy. Key regulatory aspects include:

• Good Manufacturing Practices (GMP): Manufacturers must comply with current GMP regulations as defined by regulatory bodies such as the FDA, European Medicines Agency (EMA), and others. This includes robust quality management systems, validated manufacturing processes, and controlled environmental conditions [2].
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. A DMF is a submission to regulatory authorities containing confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug products [3]. For mupirocin calcium, these filings provide evidence of the API’s specifications, manufacturing process, impurity profiles, and stability data.
• Pharmacopeial Standards: Mupirocin calcium must meet the specifications outlined in major pharmacopeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). These standards define tests and acceptance criteria for identity, purity, strength, and quality. For example, the USP monograph for Mupirocin Calcium specifies tests for assay, related substances, residual solvents, and microbial enumeration [4].
• Impurity Profiling: Manufacturers must identify and control process-related impurities and degradation products. Regulatory agencies require detailed information on the nature and levels of impurities present in the API. Specific impurities in mupirocin can arise from the synthetic route or degradation. Control strategies must be in place to ensure these impurities remain below acceptable thresholds.
• Stability Studies: Comprehensive stability studies are required to establish the retest period or shelf life of the API under various storage conditions. These studies help determine appropriate packaging and storage recommendations.

What is the Typical API Specification for Mupirocin Calcium?

Specifications for bulk mupirocin calcium API are defined by pharmacopeial monographs and can vary slightly between manufacturers based on their internal quality control and the requirements of specific regulatory filings. However, core parameters generally include:

• Appearance: A white to off-white crystalline powder.
• Identification: Tests to confirm the identity of mupirocin calcium, often including Infrared (IR) spectroscopy and high-performance liquid chromatography (HPLC) retention times.
• Assay (Mupirocin Content): Typically not less than 98.0% and not more than 102.0% of mupirocin, calculated on the dried basis. This is usually determined by HPLC.
• Water Content: A specified limit, often between 3.0% and 7.0%, determined by Karl Fischer titration.
• pH: The pH of a solution of mupirocin calcium in water is usually within a defined range, for example, between 5.0 and 7.0 for a 1% w/v solution.
• Related Substances/Impurities: Limits for specific known impurities and total impurities. These are critical for drug safety and are monitored closely. Impurities may include synthetic byproducts or degradation products. Limits are typically expressed as percentages relative to the API.
  • Individual unspecified impurity: Not more than 0.1%.
  • Total impurities: Not more than 1.0%.
• Residual Solvents: Limits for solvents used during the manufacturing process, as defined by ICH Q3C guidelines. Common residual solvents to be controlled may include ethanol, isopropanol, or ethyl acetate, with specific ppm limits.
• Heavy Metals: Limits for heavy metal content, typically not more than 10 ppm.
• Sulphated Ash/Residue on Ignition: A limit for inorganic impurities, usually not more than 0.2%.
• Microbial Enumeration Tests: Limits for the total aerobic microbial count (TAMC) and total yeast and mold count (TYMC), as well as absence of specific objectionable microorganisms, particularly for topical APIs.

These specifications are crucial for ensuring the consistent quality and safety of the final BACTROBAN product.

What are the Market Dynamics and Trends for Mupirocin API?

The market for mupirocin API is influenced by several factors:

• Generic Competition: The expiry of patents for branded BACTROBAN has led to increased production and demand for mupirocin API from generic manufacturers. This drives price competition among API suppliers.
• Antimicrobial Resistance: While mupirocin has a low risk of cross-resistance, the broader trend of increasing antimicrobial resistance globally could indirectly influence the demand for effective topical antibiotics. Mupirocin remains a valuable tool for MRSA infections [5].
• Regulatory Scrutiny: Continuous regulatory oversight and evolving GMP requirements necessitate ongoing investment in quality systems and compliance by API manufacturers. Changes in impurity control guidelines or pharmacopeial standards can impact manufacturing processes and costs.
• Supply Chain Resilience: Geopolitical events and global health crises (e.g., COVID-19) have highlighted the importance of diversified and resilient API supply chains. Pharmaceutical companies are increasingly evaluating the geographic distribution and reliability of their API sources.
• Technological Advancements: Innovations in synthetic chemistry and process optimization can lead to improved yields, reduced impurity profiles, and lower manufacturing costs for mupirocin API.

Key Takeaways

• Global production of bulk mupirocin API is concentrated among a few key manufacturers, primarily in India and Japan.
• Fuji Fine chemicals, Lupin Limited, Divi’s Laboratories, and Granules India are established suppliers with demonstrated regulatory compliance and production capacity.
• Adherence to GMP, the filing of DMFs, and meeting pharmacopeial standards (USP, Ph. Eur.) are critical for market access.
• Key API specifications include appearance, assay, water content, pH, stringent limits on related substances, residual solvents, and microbial quality.
• Market dynamics are driven by generic competition, the need for antimicrobial resistance management, and ongoing regulatory compliance.

Frequently Asked Questions

1. Are there any single-source risks for mupirocin API supply? While a few manufacturers dominate, the presence of multiple qualified suppliers in different geographic regions mitigates significant single-source risk for mupirocin API. Diversification of sourcing strategies is still advisable.

2. What are the typical lead times for sourcing bulk mupirocin API? Lead times can vary based on supplier inventory, production schedules, and order volume, but typically range from 8 to 16 weeks for substantial orders from established manufacturers with active DMFs.

3. What is the regulatory status of mupirocin API from Chinese manufacturers? While China has a large API manufacturing sector, specific GMP compliance and DMF filings for mupirocin calcium with stringent regulatory authorities like the US FDA or EMA are less widely publicized compared to Indian and Japanese counterparts. Due diligence is critical for any potential Chinese supplier.

4. How does the API quality of different manufacturers compare? API quality is generally assured by compliance with pharmacopeial standards and regulatory approvals. Differences may arise in specific impurity profiles, particle size distribution, or polymorphic forms, which can impact downstream formulation. Robust vendor qualification is essential.

5. What are the future trends expected for mupirocin API manufacturing? Expect continued emphasis on green chemistry principles to reduce solvent usage and waste, further enhancements in impurity control, and potential consolidation among API manufacturers to achieve economies of scale and enhance supply chain robustness.

Citations

[1] D. T. Lowes, M. A. D. Greenwood, S. J. Hall, D. F. R. Jones, and J. P. G. Walker, "Mupirocin: a novel antibiotic agent," Journal of Antimicrobial Chemotherapy, vol. 17, no. Supplement A, pp. 1-12, 1986. [2] U.S. Food & Drug Administration. (2023, November 15). Current Good Manufacturing Practice (CGMP) for Drugs. Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-regulation/current-good-manufacturing-practice-cgmp-drugs [3] U.S. Food & Drug Administration. (2023, March 22). Drug Master Files. Retrieved from https://www.fda.gov/drugs/drug-master-files [4] United States Pharmacopeia. (2023). United States Pharmacopeia (USP). [5] W. W. M. Fung, T. P. C. Chow, and D. L. M. Lee, "Mupirocin: a new topical antibiotic," Clinical Pharmacy, vol. 6, no. 2, pp. 128-137, 1987.